Leerink Partnrs Has Bearish Forecast for HIMS Q3 Earnings

Key Points

• Leerink Partners has revised its Q3 2025 earnings forecast for Hims & Hers Health, decreasing the estimate from $0.17 to $0.10 per share.
• Hims & Hers Health recently reported earnings of $0.17 per share, which missed analyst expectations by $0.01, and generated revenues of $544.83 million, falling short of forecasts.
• The company's stock has seen a significant price adjustment, with various analysts recently issuing downgrades and price target changes, contributing to its current average rating of "Hold."

Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) - Equities research analysts at Leerink Partnrs lowered their Q3 2025 earnings estimates for shares of Hims & Hers Health in a research report issued to clients and investors on Tuesday, August 5th. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $0.10 per share for the quarter, down from their previous forecast of $0.17. The consensus estimate for Hims & Hers Health's current full-year earnings is $0.29 per share. Leerink Partnrs also issued estimates for Hims & Hers Health's FY2026 earnings at $1.04 EPS.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%. The company had revenue of $544.83 million for the quarter, compared to analyst estimates of $550.06 million. During the same quarter last year, the company earned $0.06 EPS. The firm's revenue for the quarter was up 72.6% on a year-over-year basis.

Other equities research analysts have also issued reports about the stock. Wall Street Zen lowered shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a report on Monday, July 28th. Truist Financial raised their price objective on shares of Hims & Hers Health from $45.00 to $48.00 and gave the company a "hold" rating in a report on Thursday, July 17th. Bank of America raised their price objective on shares of Hims & Hers Health from $22.00 to $26.00 and gave the company an "underperform" rating in a report on Tuesday, April 29th. Morgan Stanley reiterated an "equal weight" rating and set a $40.00 price target on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Finally, TD Cowen lowered shares of Hims & Hers Health from a "buy" rating to a "hold" rating and cut their price target for the stock from $44.00 to $30.00 in a research note on Tuesday, April 29th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $39.83.

Hims & Hers Health Stock Down 7.6%

Hims & Hers Health stock opened at $51.30 on Thursday. Hims & Hers Health has a fifty-two week low of $13.47 and a fifty-two week high of $72.98. The company has a debt-to-equity ratio of 1.72, a quick ratio of 1.32 and a current ratio of 4.98. The firm has a 50 day moving average price of $53.79 and a 200 day moving average price of $44.63. The company has a market capitalization of $11.48 billion, a PE ratio of 64.12, a price-to-earnings-growth ratio of 2.06 and a beta of 2.08.

Institutional Trading of Hims & Hers Health

A number of institutional investors and hedge funds have recently modified their holdings of the business. Los Angeles Capital Management LLC raised its holdings in shares of Hims & Hers Health by 163.3% during the second quarter. Los Angeles Capital Management LLC now owns 98,155 shares of the company's stock worth $4,893,000 after purchasing an additional 60,878 shares during the period. Prospera Financial Services Inc acquired a new stake in shares of Hims & Hers Health during the second quarter worth $402,000. Summit Investment Advisors Inc. raised its holdings in shares of Hims & Hers Health by 187.0% during the first quarter. Summit Investment Advisors Inc. now owns 56,971 shares of the company's stock worth $1,683,000 after purchasing an additional 37,118 shares during the period. AE Wealth Management LLC acquired a new stake in shares of Hims & Hers Health during the second quarter worth $292,000. Finally, Forbes Financial Planning Inc. bought a new position in shares of Hims & Hers Health during the second quarter worth about $241,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Michael Chi sold 2,100 shares of the business's stock in a transaction that occurred on Thursday, July 24th. The shares were sold at an average price of $57.52, for a total transaction of $120,792.00. Following the completion of the sale, the insider directly owned 278,654 shares in the company, valued at $16,028,178.08. The trade was a 0.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Soleil Boughton sold 2,572 shares of the company's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $58.70, for a total transaction of $150,976.40. Following the completion of the transaction, the insider owned 155,593 shares of the company's stock, valued at $9,133,309.10. This trade represents a 1.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 737,704 shares of company stock valued at $40,644,035 in the last ninety days. Corporate insiders own 13.71% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.